Transition in the etiology of liver cirrhosis in Japan: a nationwide survey.


Journal

Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 06 08 2019
accepted: 14 11 2019
pubmed: 27 11 2019
medline: 24 7 2021
entrez: 27 11 2019
Statut: ppublish

Résumé

To assess the recent real-world changes in the etiologies of liver cirrhosis (LC) in Japan, we conducted a nationwide survey in the annual meeting of the Japan Society of Hepatology (JSH). We investigated the etiologies of LC patients accumulated from 68 participants in 79 institutions (N = 48,621). We next assessed changing trends in the etiologies of LC by analyzing cases in which the year of diagnosis was available (N = 45,834). We further evaluated the transition in the real number of newly identified LC patients by assessing data from 36 hospitals with complete datasets for 2008-2016 (N = 18,358). In the overall data, HCV infection (48.2%) was the leading cause of LC in Japan, and HBV infection (11.5%) was the third-most common cause. Regarding the transition in the etiologies of LC, the contribution of viral hepatitis-related LC dropped from 73.4 to 49.7%. Among the non-viral etiologies, alcoholic-related disease (ALD) and nonalcoholic steatohepatitis (NASH)-related LC showed a notable increase (from 13.7 to 24.9% and from 2.0 to 9.1%, respectively). Regarding the real numbers of newly diagnosed patients from 2008 to 2016, the numbers of patients with viral hepatitis-related LC decreased, while the numbers of patients with non-viral LC increased. HCV has remained the main cause of LC in Japan; however, the contribution of viral hepatitis as an etiology of LC is suggested to have been decreasing. In addition, non-viral LC, such as ALD-related LC and NASH-related LC, is suggested to have increased as etiologies of LC in Japan.

Sections du résumé

BACKGROUND BACKGROUND
To assess the recent real-world changes in the etiologies of liver cirrhosis (LC) in Japan, we conducted a nationwide survey in the annual meeting of the Japan Society of Hepatology (JSH).
METHODS METHODS
We investigated the etiologies of LC patients accumulated from 68 participants in 79 institutions (N = 48,621). We next assessed changing trends in the etiologies of LC by analyzing cases in which the year of diagnosis was available (N = 45,834). We further evaluated the transition in the real number of newly identified LC patients by assessing data from 36 hospitals with complete datasets for 2008-2016 (N = 18,358).
RESULTS RESULTS
In the overall data, HCV infection (48.2%) was the leading cause of LC in Japan, and HBV infection (11.5%) was the third-most common cause. Regarding the transition in the etiologies of LC, the contribution of viral hepatitis-related LC dropped from 73.4 to 49.7%. Among the non-viral etiologies, alcoholic-related disease (ALD) and nonalcoholic steatohepatitis (NASH)-related LC showed a notable increase (from 13.7 to 24.9% and from 2.0 to 9.1%, respectively). Regarding the real numbers of newly diagnosed patients from 2008 to 2016, the numbers of patients with viral hepatitis-related LC decreased, while the numbers of patients with non-viral LC increased.
CONCLUSIONS CONCLUSIONS
HCV has remained the main cause of LC in Japan; however, the contribution of viral hepatitis as an etiology of LC is suggested to have been decreasing. In addition, non-viral LC, such as ALD-related LC and NASH-related LC, is suggested to have increased as etiologies of LC in Japan.

Identifiants

pubmed: 31768801
doi: 10.1007/s00535-019-01645-y
pii: 10.1007/s00535-019-01645-y
pmc: PMC7026312
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

353-362

Références

Lancet. 2008 Mar 8;371(9615):838-51
pubmed: 18328931
Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3
pubmed: 29908364
J Gastroenterol. 2019 Aug;54(8):752-761
pubmed: 30868245
Gastroenterology. 2019 Jan;156(2):297-310
pubmed: 30391470
World J Gastroenterol. 2014 Oct 7;20(37):13546-55
pubmed: 25309085
Hepatology. 2017 Oct;66(4):1020-1022
pubmed: 28714210
J Gastroenterol. 2018 Feb;53(2):181-196
pubmed: 29177681
J Gastroenterol. 2019 Sep;54(9):829-836
pubmed: 31161311
Hepatol Res. 2013 Oct;43(10):1020-31
pubmed: 23347437
Hepatol Res. 2019 Mar;49(3):296-303
pubmed: 30367534
Hepatol Res. 2017 May;47(6):487-496
pubmed: 28326651
J Gastroenterol. 2010;45(1):86-94
pubmed: 19789837
J Gastroenterol. 2018 Oct;53(10):1142-1150
pubmed: 29626296
Hepatol Res. 2019 Dec;49(12):1365-1373
pubmed: 31323165
Oncology. 2002;62 Suppl 1:8-17
pubmed: 11868791
Hepatol Res. 2015 Jan;45(1):59-74
pubmed: 24965914
J Gastroenterol. 2019 Apr;54(4):367-376
pubmed: 30498904
Euroasian J Hepatogastroenterol. 2018 Jan-Jun;8(1):77-80
pubmed: 29963470

Auteurs

Hirayuki Enomoto (H)

Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Mukogawa-cho 1-1, Nishinomiya, Hyogo, 663-8501, Japan.

Yoshiyuki Ueno (Y)

Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, Japan.

Yoichi Hiasa (Y)

Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.

Hiroki Nishikawa (H)

Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Mukogawa-cho 1-1, Nishinomiya, Hyogo, 663-8501, Japan.
Center for Clinical Research and Education, Hyogo College of Medicine, Nishinomiya, Japan.

Shuhei Hige (S)

Department of Hepatology, Sapporo Kosei General Hospital, Sapporo, Japan.

Yasuhiro Takikawa (Y)

Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.

Makiko Taniai (M)

Internal Medicine, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.

Toru Ishikawa (T)

Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Japan.

Kohichiroh Yasui (K)

Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Akinobu Takaki (A)

Department of Gastroenterology and Hepatology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.

Koichi Takaguchi (K)

Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.

Akio Ido (A)

Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Masayuki Kurosaki (M)

Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino, Japan.

Tatsuya Kanto (T)

Hepatitis Information Center, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Tokyo, Japan.

Shuhei Nishiguchi (S)

Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Mukogawa-cho 1-1, Nishinomiya, Hyogo, 663-8501, Japan. nishiguc@hyo-med.ac.jp.
Center for Clinical Research and Education, Hyogo College of Medicine, Nishinomiya, Japan. nishiguc@hyo-med.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH